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Summary. This review seeks to re-introduce cystic fibrosis (CF) clinicians to the pharmacologyof
drug–drug interactions among medications commonly used in CF and provide a framework for
understanding these interactions among medications outside the scope of this discussion. We
here focus on drugs impacted by the cytochrome P-450 (CYP450) enzyme system and on
interactions involving antimicrobials, psychotropic medications, and cystic fibrosis transmem-
brane conductance regulator (CFTR)modulators. Particular attention is neededwhen prescribing
rifampin, azole antifungals and the CFTR modulators, ivacaftor, and lumacaftor/ivacaftor, in
combination with other medications. The complexities of these interactions provide a strong
rationale for casemanagement by pharmacists and pharmacologists as a routine part of CF care.
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INTRODUCTION
Utilization of combination medical therapies for
cystic fibrosis (CF), involving an expanding array of
therapeutic agents,1 has been met with optimism for
further substantial improvements in survival and quality
of life accompanied by challenges in design of regimens
for individual patients. As drug development has
proceeded in the last two decades, first-in-class medi-
cations have typically been evaluated in the context of
continued use of existing therapies yielding potential for
greater treatment complexity.2,3 In a sample of CF adults
queried in 2006, median number of daily medications
reported was seven (range 0–20), including two nebulized
medications, and time to completion of daily treatment
including airway clearance was 2–3 hr.2 Treatment
complexity scores of children were nearly as high as of
adults in a large observational study using data from a
similar time frame.4 Indeed, the emerging understanding
of the contribution of early airway infection and
inflammation to the pathogenesis of CF lung disease
motivates greater intensity of therapy beginning in early
childhood. This is not a new concept—but one with new
twists given anticipated frequency of overlapping short-
term and cumulative exposures to medications over a
lifetime, particularly in the context of availability of new
agents, like cystic fibrosis transmembrane conductance
regulator (CFTR) modulators, and more widespread use
of antifungal and antimycobacterial agents recognized to
have potential for significant adverse drug reactions,
including drug-drug interactions.
The prevalence and implications of multiple over-
lapping drug exposures, so-called “polypharmacy,”
have been studied primarily in elderly patients.5–7
Polypharmacy is defined most commonly as concurrent
use of five or more drugs.8 In general, risk of adverse drug
reactions increases with total number of daily medica-
tions.8,9 Prevalence and characteristics of potential drug–
drug interactions in children have been highlighted
recently by a retrospective cohort study of drug use in
hospitalized children using a large administrative data-
base.10–12 In analyses of nearly 500,000 hospitalizations
in 43 U.S. children’s hospitals, 49% of children were
exposed to at least one potential drug–drug interaction.
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Five percent of hospitalizations included a potential drug–
drug interaction categorized as “contraindicated,” and
41% had an exposure of potential “moderate” severity.11
Older age, longer hospitalization, and having a complex
chronic condition increased the likelihood of potential
drug–drug interaction.11 These data offer new perspective
on the frequency of potential drug–drug interactions
among hospitalized children and adolescents that is
relevant to CF patients who have high daily medication
requirements, even as outpatients.
While few relevant data exist, studies suggest that
physician knowledge of drug–drug interactions is
limited.13,14 Here we do not attempt a comprehensive
review of specific drug–drug interactions in CF manage-
ment, which is well beyond the scope of a single review.
This review seeks to re-introduce CF clinicians to the
pharmacology of drug–drug interactions among medi-
cations commonly used in CF and provide a framework
for understanding these interactions among medications
outside the scope of this discussion. Two recent trends in
CF care are the introduction of CFTR modulators and
emphasis on the importance of mental health in chronic
disease management.15 As a complement to other recent
reviews,3 we, therefore, focus on drugs impacted by
the cytochrome P-450 (CYP450) enzyme system and
on interactions involving antimicrobials, psychotropic
medications, and CFTR modulators.
DRUG METABOLISM PATHWAYS: GENERAL
CONSIDERATIONS
A large proportion of clinically relevant drug inter-
actions are related to metabolism by the cytochrome
P-450 (CYP450) enzymes. The CYP450 enzymes are
found in many cells, but are most highly concentrated in
hepatocytes.16 Activity of CYP450 enzymes tends to
increase with age, though most reach similar activity to
that of adults by age 2 years.17 The CYP450 enzymes are
grouped into families (1–3), subfamilies (A–E), and
individual gene number.More than 90% of drug oxidation
can be attributed to six enzymes: CYP1A2, 2C9, 2C19,
2D6, 2E1, and 3A4.16 For the purposes of this article,
CYP3A4, CYP2C9, and 2C19 will be the primary
focus, as they are responsible for a significant number
of drug interactions relevant to CF.
Drug activity on CYP450 enzymes can result in either
induction or inhibition of the enzyme (Fig. 1). Enzyme
induction causes enhanced metabolism of other drug
substrates, usually leading to decreased exposure and
potentially reduced therapeutic efficacy. However, if the
enzyme substrate is a prodrug that requires metabolism to
one or more active metabolites, induction of the CYP450
enzyme can result in increased levels of active metabolite,
potentially resulting in toxicity.Onset and offset of enzyme
induction is gradual, as it is dependent on steady state
levels of the inducer as well as synthesis of new enzyme.16
Alternatively, CYP450 enzyme inhibition usually results
in increased concentrations of drug substrates, potentially
leading to toxicity. Onset of inhibition is faster, beginning
with the initial doses of the inhibitor and reachingmaximal
effect at steady state.16
In addition to drug properties, an individual patient’s
genotype can play an important role in drug metabolism.
Genetic polymorphisms of a given CYP450 gene can
result in variation of that enzyme’s activity. For the most
part, patients can be classified as either poor metabolizers,
Fig. 1. Effects of CYP450 inducers and inhibitors on (A) CYP450-metabolized drug substrates and
(B) CYP450-metabolized prodrugs.
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extensive metabolizers, or ultrarapid metabolizers. A
classic example of the differences between different
phenotypes is response to codeine, which requires
metabolism to its active metabolite morphine by
CYP2D6 in order for patients to receive benefit. In the
case of poor metabolizers, these patients may not receive
benefit from codeine because they are unable to convert
the parent drug to its active metabolite; alternatively,
ultrarapid metabolizers may experience toxicity due to
the overabundance of morphine derived from a seemingly
normal dose of codeine. As more is learned about the role
of specific pharmacogenetic mutations on patients’
response to medications, the clinician will need to take
this into consideration when determining appropriate
therapy and dosing.
Commonly used drugs in CF management which have
significant interaction with CYP450 enzymes are shown
in Table 1.
CYP3A4 Inducers
CYP3A4 is involved in the metabolism of approxi-
mately 50% of currently available medications.18 For that
reason, it is often implicated in drug–drug interactions.
Rifampin and rifabutin are potent inducers of CYP3A4,
increasing hepatic CYP3A4 content by 2.4- to 4.7-fold and
intestinal content by five- to eightfold.19 This induction
likely reaches maximal effect approximately 1 week after
starting rifampin, based on pharmacokinetic principles.
Among its numerous interactions, rifampin proves
particularly problematic when given concomitantly
with azole antifungals, which are themselves potent
CYP3A4 inhibitors of varying degrees. When adminis-
tered together, rifampin reduced voriconazole area under
curve (AUC) by 96% and resulted in undetectable
itraconazole concentrations.20,21 Fluconazole and posa-
conazole are affected to a lesser extent, with decreases in
AUC of 23% and 43%, respectively.22,23 Other anti-
microbials can also be impacted by rifampin. Clarithro-
mycin is metabolized significantly by CYP3A4, with
plasma concentrations reduced by an average of 44%
when given in combination with rifampin.24 In contrast,
azithromycin is metabolized by other pathways and is not
impacted significantly. Doxycycline is also affected,with a
reduction in AUC by 54% and half-life from 14 to 9 hr
that may necessitate more frequent dosing when used in
combination.25 When utilizing a CYP3A4 inducer, such
as rifampin, with a substrate of the same enzyme,
consideration should be given to the need for increased
dose and/or frequency to account for potential drug–drug
interactions. Changes in drug dosing should be individual-
ized to the specific medications being used (Table 1).
CYP3A4 Inhibitors
CYP3A4 inhibitors relevant to many CF patients
include azole antifungals, as mentioned above; clari-
thromycin; and some selective serotonin reuptake
inhibitors (SSRIs). In comparison with rifampin, these
medications can result in increased concentrations of
affected substrates, which may lead to toxicity. One
notable example of such an interaction is that of azole
antifungals and corticosteroids. Several case reports
note adverse effects, including hypothalamic-pituitary
axis suppression, adrenal insufficiency, and growth failure,
when inhaled corticosteroids were used chronically with
itraconazole or fluconazole.26–28 These reports point out
the potential interaction betweenmedications that are quite
commonly utilized together (Table 1).
CYP2C9/2C19 Inducers
In addition to its activity on CYP3A4, rifampin is a
potent inducer of bothCYP2C9andCYP2C19. In contrast,
rifabutin does not affect these enzymes. Although these
TABLE 1—CYP450 Enzyme Interactions (Moderate or Strong) With Some Commonly Used Medications in CF and Mental
Health Discussed in This Review
Cytochrome Inducers1 Inhibitors2 Substrates3
CYP3A4 Rifabutin, rifampin Clarithromycin, erythromycin,
fluconazole, itraconazole,
posaconazole, voriconazole
Citalopram, clarithromycin, corticosteroids,
cyclosporine, doxycycline, erythromycin,
escitalopram, guanfacine, itraconazole,
lansoprazole, midazolam, mirtazapine,
rifabutin, tacrolimus, voriconazole
CYP2C9 Rifampin Fluconazole, omeprazole, voriconazole Fluoxetine, ibuprofen, voriconazole
CYP2C19 Rifampin Esomeprazole, fluconazole,
fluoxetine, omeprazole,
sertraline, voriconazole
Citalopram, escitalopram, esomeprazole,
lansoprazole, omeprazole, pantoprazole,
posaconazole, voriconazole
CYP1A2 Rifampin Ciprofloxacin Duloxetine, mirtazapine, theophylline
CYP2D6 Duloxetine, fluoxetine, paroxetine, sertraline Atomoxetine, fluoxetine, mirtazapine,
paroxetine
1Inducers increase CYP450 enzyme activity and therefore tend to reduce exposure to substrates of the enzyme.
2Inhibitors decrease CYP450 enzyme activity and therefore tend to increase exposure to substrates of the enzyme.
3Substrates are drugs which are metabolized by the CYP450 enzyme.
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enzymes are not as commonly involved in drug metabo-
lism as CYP3A4, they still present several challenges
regarding drug–drug interactions. In particular, many
non-steroidal anti-inflammatory drugs (NSAIDs) are
substrates of CYP2C9.29 Evidence supporting this
interaction is limited, but it is important to consider,
particularly for patients utilizing high-dose ibuprofen for
its anti-inflammatory properties. Patients started on
rifampin may require additional monitoring of ibuprofen
concentrations around 2–4 weeks after initiation to
ensure that levels remain within the therapeutic range.
Additionally, patients may require higher doses in order to
achieve pain relief.
CYP2C9/2C19 Inhibitors
Inhibitors of CYP2C19 include fluconazole, voricona-
zole, and the proton pump inhibitors (PPIs).30 Some PPIs,
particularly omeprazole, also inhibit CYP2C9 to varying
degrees. The interaction between these two drug classes
is variable. When given together, omeprazole resulted
in an increase in voriconazole AUC by 41%, while
co-administration of esomeprazole with posaconazole
resulted in a decrease in posaconazole AUC by
32%.31,32,23 Somevariability in results is likely attributable
to the fact that posaconazole absorption is pH-dependent,
with decreased gastric pH being ideal for optimal
absorption. Monitoring of pharmacokinetic concentrations
of azole antifungals,wherepossible, is recommendedwhen
these medications are utilized in combination with PPIs to
ensure patients reach therapeutic levels, since the potential
for both treatment failure and toxicity exists. Azole trough
concentrations can be obtained 5–7 days after adding
potentially interacting medications, as this should reflect
the new steady state of the azole antifungal. Additionally,
many of the SSRIs are substrates of CYP2C19, including
citalopram and escitalopram (Table 1). Because PPIs
inhibit CYP2C19, their use with SSRIs may result in
increased exposure to the SSRI. In particular, citalopram
prescribing information recommends limiting the dose to a
maximum of 20mg/day in patients receiving a CYP2C19
inhibitor, such as esomeprazole or omeprazole.33 Canadian
prescribing information for escitalopram, the S-isomer of
citalopram, recommends limiting dosing to 10mg/day
when used in combinationwith omeprazole; however, U.S.
product labeling does not contain this recommenda-
tion.34,35 Patients taking other SSRIs should be monitored
for efficacy when taking in combination with a PPI.
SPECIFIC DRUG TYPES COMMONLY USED IN
CF CARE
Antimicrobials and Drug–Drug Interactions
As previously discussed, antimicrobials used in the
treatment of non-tuberculous mycobacterial infections,
like rifampin and clarithromycin, and the azole anti-
fungals are known contributors to significant drug–
drug interactions found in the CF population. Other
potentially clinically significant interactions involving
antimicrobials include additive QT prolongation and
nephrotoxicity.
QT Prolongation
Many medications can contribute to QT-interval
prolongation. Two classes of antibiotics often used in
the CF population that can contribute to this phenomenon
are macrolides and fluoroquinolones. Within the macro-
lide antibiotic class, clarithromycin and erythromycin
appear to contribute most significantly to potential QT
prolongation.36 A retrospective study in 2012 noted an
increased risk of cardiovascular death in adult patients
taking azithromycin, which ultimately resulted in a U.S.
Food and Drug Administration (FDA) issued Drug Safety
Communication focused on azithromycin’s risk of
potentially fatal heart rhythms.37,38 Within the fluoro-
quinolone class, moxifloxacin appears to contribute more
than ciprofloxacin and levofloxacin to QT prolongation.39
As more medications are implicated in QT prolongation,
it is important for the clinician to assess a patient’s risk
factors as well as potential medications that may
contribute. Resources are available online, including
CredibleMeds1, a database that can assist the clinician in
determining the likelihood that a particular medication
may contribute to QT prolongation through its risk-
stratification process.40
Nephrotoxicity
Another important category of drug–drug interactions
to consider in CF patients is use of concomitant
nephrotoxic antimicrobials. Many commonly utilized
antibiotics can contribute to nephrotoxicity, including
vancomycin, aminoglycosides, piperacillin/tazobactam,
sulfamethoxazole/trimethoprim, carbapenems, and colis-
tin. The 2005 TOPIC study demonstrated decreased
nephrotoxicity with extended-interval dosing of tobra-
mycin, with a mean change in creatinine of 4.5% for
patients receiving once daily tobramycin versus 3.7% for
those receiving traditional three times daily dosing.41
Care should be taken to avoid combinations of
nephrotoxic medications where possible and to ensure
closemonitoring for renal function in patients who require
multiple nephrotoxins.
Mental Health Drugs
CF, like other chronic diseases, carries risk of mental
health issues including depression and anxiety.42 Thus, the
CF clinician faces a high likelihood of encountering
children who are being considered for or treated with
pharmacologic agents for mental health indications, some
of which (e.g., SSRIs and psychostimulants) may have
significant interaction with commonly used drugs for CF
S64 Jordan et al.
Pediatric Pulmonology
lung disease. While therapeutic drug monitoring for
psychotropic medications is advocated by some,43 proac-
tive awareness and adjustment of dosing may be more
practical in pediatric patients.
SSRI and Linezolid
Linezolid is a weak inhibitor of monoamine oxidase
(MAO), the enzyme responsible for metabolism of the
neurotransmitters epinephrine, norepinephrine, serotonin,
and dopamine. Its affinity for MAO gives linezolid the
theoretical potential to cause serotonin toxicity, especially
when used in combination with another serotonergic agent.
Serotonin syndrome is a triad of symptoms, including
mental status changes, neuromuscular abnormalities, and
autonomic hyperactivity.44 A literature review in 2006
identified 13 cases of serotonin syndrome when linezolid
was used concomitantlywith SSRIs or other agents used for
treatment of depression and anxiety including paroxetine,
fluoxetine, mirtazapine, and sertraline,45 and 29 cases
(13 serious) were reported in a post marketing survey.46
Other SSRIs used for treatment of anxiety or depression in
children and adolescents include duloxetine, citalopram,
and escitalopram. A low incidence (3%) of serotonin
syndromewas reported byTaylor et al.47who suggested that
a washout period after stopping SSRI is not necessary for
patients needing linezolid treatment. Similarly, Butterfield
et al.48 reported an evaluation of concomitant use of
linezolid and serotonergic agents from 20 Phase III and IV
comparator-controlled clinical studies on treatment of
various Gram-positive infections and found a low (<1%)
incidence of serotonin syndrome. Thus, while the actual
incidence of serotonin syndrome resulting from concomi-
tant SSRI and linezolid use appears to be quite low, the
frequent use of these agents in CF patients suggests the need
for CF clinicians to be cautious. Preclinical studies suggest
that tedizolid, a novel oxazolidinone antibiotic with a
longer half-life and greater potency against gram-positive
bacteria than linezolid, shows little actual MAO inhibition
and may therefore have lower risk for adverse interactions
with serotonergic agents.49 Tedizolid is currently in clinical
trials.
Attention Deficit Hyperactivity Disorder (ADHD) Medications
Guanfacine is a selective [alpha]2A-adrenoreceptor
agonist that activatescentral nervous systemnorepinephrine
receptors. This action results in reduced peripheral
sympathetic tone, which was its original indication as an
antihypertensive. It should not be withdrawn suddenly
because of risk of hypertensive crisis, and hence, patients
or their parents should be educated about the need for
perfect adherence.50 It is used clinically as either
monotherapy or adjunct therapy (along with psychosti-
mulants) for the treatment of ADHD because of its
hypothesized action of increasing network connections
in the prefrontal cortex.51 Dose reductions and monitor-
ing are recommended if used in patients with
compromised liver and/or kidney function.50 Guanfacine
is primarily metabolized by CYP3A4. The clinician
should consider increasing its dose by twofold when
adding a strong CYP3A4 inducer such as rifampin.
Conversely, guanfacine dose should be reduced twofold
in the presence of a strong CYP3A4 inhibitor such as
azole antifungals or clarithromycin.
Atomoxetine is a norepinephrine reuptake inhibitor
used for treatment of ADHD. It is metabolized primarily
through the CYP2D6 enzymatic pathway. Thus, it should
be initiated at reduced dose in patients receiving strong
CYP2D6 inhibitors (e.g., paroxetine and fluoxetine).
There have been reports of atomoxetine use associated
with severe liver damage52; thus, caution should be
exercised in its use in patients with CF related liver
disease. It has been advocated to hold atomoxetine during
treatment of CF patients with linezolid, a monoamine
oxidase inhibitor.53
Stimulant-based therapies approved in the United
States for treatment of ADHD include the amphetamines
and methylphenidate. These agents inhibit dopamine
transporter and norepinephrine transporter, thereby
inhibiting the reuptake of these neurotransmitters. Both
stimulants also inhibitMAO, the enzyme that metabolizes
these catecholamines.50 Examples of stimulants used in
treatment of ADHD include amphetamine, lisdexamfet-
amine, methylphenidate, and dexmethylphenidate. Line-
zolid is a mild nonselective MAO inhibitor and thus in
combination with these agents, has the potential to trigger
excessive adrenergic activity.54 While this effect has
been mild when directly tested,55 it is recommended to
utilize lower initial doses of these drugs in combination
with linezolid, and to monitor for side effects such as
hypertension.56
CFTR Modulators
The development of CFTRmodulators and potentiators
heralds an exciting new era of personalized treatment for
CF patients, with agents specific for mutation class
targeting the basic molecular defect. As these agents are
used chronically and many existing CF treatments will
need to be continued, it is important that clinicians be
aware of potential drug-drug interactions (Tables 2 and 3).
Ivacaftor
Ivacaftor is a novel CFTR modulator approved for use
in patients ages 2 and older with one of nine gating
mutations, including G551D and R117H. Ivacaftor itself
is a substrate of CYP3A4 and is, therefore, affected when
given in combination with other medications that act on
CYP3A4. According to the prescribing information
available, the dosing frequency should be reduced to
once daily in patients also taking moderate CYP3A4
inhibitors, such as fluconazole, and to twice weekly in
patients taking strong CYP3A4 inhibitors, including
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ketoconazole, itraconazole, posaconazole, voriconazole,
telithromycin, and clarithromycin.57 Additionally, pa-
tients should avoid grapefruit juice and Seville oranges
while taking ivacaftor, as these may also increase
ivacaftor concentrations due to CYP3A4 inhibition.
Although evidence in patients on adjusted therapy is
limited, one sibling case report noted similar improve-
ments in lung function, sweat chloride level, and weight
over 36 weeks in two siblings taking ivacaftor.58 One
sibling was given the standard dose of ivacaftor, 150mg
twice daily, while the other was prescribed 150mg
twice weekly because he was also on itraconazole.
Interestingly, the sibling who was on the reduced dose
experienced an increase in FEV1 from 47% to 84%
predicted, while his sibling’s FEV1 increased from 55%
to 71% predicted over the same time period. In patients
taking strong CYP3A4 inducers, such as rifampin,
phenobarbital, carbamazepine, phenytoin, and St. John’s
Wort (a medicinal plant used as an antidepressant),
ivacaftor should be avoided. Co-administration of ivacaftor
with rifampin resulted in an approximately ninefold
decrease in AUC.
Ivacaftor also acts as a weak CYP3A4 and P-
glycoprotein (P-gp) inhibitor. Recently, a four-part
pharmacokinetic study pairing ivacaftor with medications
that are sensitive substrates of CYP2C8 (rosiglitazone),
CYP3A4 (midazolam), and CYP2D6 (desipramine), as
well as a combined oral contraceptive demonstrated
ivacaftor’s effect on each.59 When given in combination,
ivacaftor had minimal effect on the AUC of rosiglitazone
and desipramine. However, ivacaftor did increase the
AUC of midazolam by 54%, and also decreased the oral
clearance by 35% and increased the half-life from
4.1 to 5.5 hr. Based on this data, it is important to
consider dose adjustments and appropriate monitoring
when giving ivacaftor concomitantly with substrates of
CYP3A4 and P-gp, including benzodiazepines, cyclo-
sporine, and tacrolimus. Timing of drug levels should be
based on the half-life of the medication being examined.
Ivacaftor given with a contraceptive resulted in a 22%
increase in ethinyl estradiol maximum concentration,
but AUC was not impacted. For this reason, the co-
administration of ivacaftor with oral contraceptives is
not expected to impact the safety or efficacy of the
contraceptive.
Lumacaftor/ivacaftor
Lumacaftor/ivacaftor is the first FDA-approved com-
binationpotentiator/corrector therapy for patients 12years
and older who are homozygous for the delF508
mutation.60 Lumacaftor/ivacaftor, similar to ivacaftor
alone, is a substrate of CYP3A4 and therefore requires
dose adjustment when initiating in patients taking strong
CYP3A4 inhibitors. In this scenario, patients should
receive one tablet daily for the first week of treatment,
after which time the dose can be increased to the usual
dose of two tablets twice daily. Without dose adjustment,
co-administration of lumacaftor/ivacaftor with itracona-
zole, a strong CYP3A4 inhibitor, resulted in increased
exposure to ivacaftor by 4.3-fold. Similar to ivacaftor,
lumacaftor/ivacaftor should be avoided in combination
with strong CYP3A4 inducers due to the potential for
TABLE 2—Ivacaftor Drug–Drug Interactions
Drug name/class
Mechanism of
interaction Effect of interaction Suggested intervention
Azole antifungals (itraconazole,
ketoconazole, voriconazole,
posaconazole)
CYP3A4 inhibition Increases ivacaftor
exposure
When used in combination, decrease
ivacaftor dose to twice weekly
Fluconazole CYP3A4 inhibition Increases ivacaftor
exposure
When used in combination, decrease
ivacaftor dose to daily
Macrolides (erythromycin,
clarithromycin)
CYP3A4 inhibition Increases ivacaftor
exposure
When used in combination with erythromycin,
decrease ivacaftor dose to daily. When used
in combination with clarithromycin,
decrease ivacaftor dose to twice weekly
Does not apply to azithromycin
Rifampin/rifabutin CYP3A4 induction Decreases ivacaftor
exposure
Avoid combination
Immunosuppressants (cyclosporine,
everolimus, sirolimus, tacrolimus)
CYP3A4 inhibition Increases
immunosuppressant
levels
Monitor immunosuppressant levels; will
likely require decreased
immunosuppressant doses
Benzodiazepines (midazolam) CYP3A4 inhibition Increases
benzodiazepine
exposure
Consider an alternative agent; monitor for
toxicity
Ibuprofen CYP2C9 inhibition Increases ibuprofen
exposure
Recommend checking levels 2–4 weeks after
initiation; may require lower doses
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reduced effectiveness with reduced drug exposure. When
given in combination with rifampin, exposure to ivacaftor
was decreased by 57%.
Lumacaftor/ivacaftor acts on several of the CYP450
enzymes, including induction of CYP3A4, CYP2C9,
CYP2C19, CYP2B6, as well as P-gp. The induction of
CYP3A4 is most notable, as lumacaftor/ivacaftor has a
net strong induction of these enzymes. Because the azole
antifungals are substrates of CYP3A4, it is likely that the
strong induction of CYP3A4 by lumacaftor/ivacaftor will
reduce the concentrations of azole antifungals signifi-
cantly, possibly making them ineffective. Therefore, it is
recommended to consider other antifungal agents that are
less likely to be impacted by lumacaftor/ivacaftor. Other
CYP3A4 substrates, including those that are sensitive
or have narrow therapeutic index, should be avoided in
combination with lumacaftor/ivacaftor. These include
midazolam, cyclosporine, everolimus, sirolimus, and
tacrolimus. Levels of some antibiotics, including clari-
thromycin and erythromycin, are also reduced when
combined with lumacaftor/ivacaftor, and alternatives
should be considered.
Although the mechanism of the interaction is not well
defined, hormonal contraceptive exposure may be
reduced when used in combination with lumacaftor/
ivacafator. This potentially affects all routes of contracep-
tive administration, including oral, injectable, transdermal,
and implantable. Because of this, hormonal contraceptives
should not be relied on as the sole method of contraception
in patients taking lumacaftor/ivacaftor. Patients should be
counseled to utilize other methods of contraception.
Lumacaftor/ivacaftor also exhibits in vitro induction of
CYP2C9 and CYP2C19, which can affect exposure to
several medications classes often utilized in CF patients.
TABLE 3—Lumacaftor/Ivacaftor Drug–Drug Interactions
Drug name/class
Mechanism of
interaction Effect of interaction Suggested intervention
Azole antifungals
(fluconazole, itraconazole,
ketoconazole, voriconazole,
posaconazole)
CYP3A4 induction and
inhibition1
Decreases azole levels Avoid when possible; azoles likely to be
ineffective
Increases lumacaftor/ivacaftor
exposure
If starting lumacaftor/ivacaftor in patient on
azole already, start with one tablet daily for
1 week, then increase to recommended daily
dose
Benzodiazepines (midazolam) CYP3A4 induction Decreases benzodiazepine
exposure
Consider an alternative agent
Macrolides (erythromycin,
clarithromycin)
CYP3A4 induction Decreases macrolide exposure If initiating lumacaftor/ivacaftor in patient on
clarithromycin, start with one tablet daily for
1 week, then increase to recommended daily
dose
Increases lumacaftor/ivacaftor
exposure
Does not apply to azithromycin1
Rifampin/rifabutin CYP3A4 induction Decreases lumacaftor/ivacaftor
exposure
Avoid combination
Immunosuppressants
(cyclosporine, everolimus,
sirolimus, tacrolimus)
CYP3A4 induction Decreases immunosuppressant
levels
Avoid combination; will require increased
immunosuppressant doses
Corticosteroids CYP3A4 induction Decreases steroid exposure Monitor for effectiveness; may require higher
steroid doses
Proton pump inhibitors
(omeprazole, lansoprazole,
pantoprazole)
CYP2C19 induction Decreased PPI exposure Monitor for effectiveness
H2-receptor antagonists
(ranitidine, famotidine)
CYP2C19 induction Decreased H2-receptor
antagonist exposure
Monitor for effectiveness
Hormonal contraceptives Decreased contraceptive
effectiveness
Avoid if possible; hormonal contraceptives
should not be relied upon as sole method of
contraception
Increased menstrual abnormality
events
Applies to oral, injectable, transdermal, and
implantable contraceptives
SSRIs (citalopram,
escitalopram, sertraline)
CYP2C9 induction Decreased SSRI exposure Monitor for effectiveness; may require higher
SSRI doses
Ibuprofen CYP2C9 induction Decreased ibuprofen exposure Recommend rechecking levels 2–4 weeks after
initiation; may require higher ibuprofen doses
1Lumacaftor/ivacaftor is an inducer/substrate and the azoles are inhibitors/substrates.
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Both PPIs and H2 receptor antagonists are metabolized
by CYP2C19, and exposure to these medication classes
may be reduced when utilized in combination with
lumacaftor/ivacaftor. Similarly, some of the SSRIs,
particularly citalopram, escitalopram, fluoxetine, and
sertraline, may also have reduced exposure and efficacy
when used in combination with lumacaftor/ivacaftor.
Because of this interaction, patients may require higher
doses of these medications to obtain clinical efficacy, and
patients should be monitored closely for any change in
clinical response to SSRI after starting lumacaftor/
ivacaftor. Ibuprofen is also a substrate of CYP2C9 and
CYP2C19, and therefore may be reduced when used in
combination with lumacaftor/ivacaftor. This is of partic-
ular importance for patients utilizing high-dose ibuprofen
for its anti-inflammatory benefits. These patients should
have ibuprofen levels checked within 2–4 weeks after
starting lumacaftor/ivacaftor to ensure that peak concen-
trations are still within the appropriate therapeutic range,
as both subtherapeutic and supratherapeutic levels have
potential adverse effects.
Overall, lumacaftor/ivacaftor is associated with several
significant drug–drug interactions, and the extent of its
effect on some of the CYP450 enzymes is still not well
defined. Thorough screening for potential drug–drug
interactions should be done prior to initiation of
lumacaftor/ivacaftor, and patients should be closely
monitored for any potential adverse effects that may be
associated with drug–drug interactions.
CONCLUSIONS
Vigilance is needed to identify combinations of
medications that can alter drug bioavailability by
inducing or inhibiting CYP450. These combinations
may require adjustment in dose or drug substitution along
with specific monitoring to achieve efficacy while
avoiding toxicity. Particular attention is needed when
prescribing rifampin, azole antifungals and the CFTR
modulators, ivacaftor and lumacaftor/ivacaftor, in com-
bination with other medications. Other mechanisms
prompt caution in the use of medications that can prolong
QT interval, SSRIs, and some ADHD medications in
combination. Resources that list interactions and com-
puter software tools that provide paired comparisons of
medications or evaluation of full medication profiles
can heighten clinician awareness of potential interac-
tions.40,61 Because it is difficult for CF clinicians to
keep all these interactions in mind, case management
by pharmacists/pharmacologists for CF care is highly
recommended for identification of and education con-
cerning drug–drug interactions and other potentially
troublesome drug combinations. Research evaluating
comparative effectiveness of existing therapies may
provide a framework for individualized, potentially
simplified regimens in the midst of ongoing development
and implementation of new therapeutics.62
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